Stock HEPA HEPION PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Market Closed - Nasdaq
Other stock markets
 21:30:00 08/05/2024 BST 		5-day change 1st Jan Change
1.31 USD -4.38% Intraday chart for Hepion Pharmaceuticals, Inc. -3.68% -59.57%
04-22 Sector Update: Health Care Stocks Increase Late Afternoon MT
04-22 Sector Update: Health Care MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial
AQ
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
AQ
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
AQ
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
AQ
Hepion Pharmaceuticals to Present at NASH-TAG 2024
AQ
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
AQ
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
AQ
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
AQ
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
AQ
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
AQ
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
AQ
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
AQ
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program
AQ
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
AQ
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
AQ
Hepion Pharmaceuticals Announces Management Changes
AQ
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
AQ
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat
AQ
Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
AQ
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HEPA Stock
  4. News Hepion Pharmaceuticals, Inc.
  5. Press Releases